1,031 Photos and videos
Ricardo Carvalho retweeted
Jun 13
Beyond second-line therapy: Strategic sequencing of... : Hepatology journals.lww.com/hep/abstrac…
4
14
1,262
Ricardo Carvalho retweeted
Jun 12
🟩GCSF use in oncology
NCCN guideline summary
#cancer #oncology #MedX #blood @OncoAlert @weoncologists @realbowtiedoc @crisbergerot
2
57
134
4,784
Ricardo Carvalho retweeted
Jun 10
Trends and Outcomes of Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases Using the National Cancer Database | JCO Oncology Advances ascopubs.org/doi/10.1200/OA-…
8
19
1,404
Ricardo Carvalho retweeted
Jun 11
Two positive phase III perioperative gastric cancer immunotherapy trials.
📌 MATTERHORN
• Durvalumab FLOT
• EFS HR 0.71
• pCR 19.2% vs 7.2%
📌 ASTRUM-006
• Serplulimab SOX
• EFS HR 0.73
• pCR 22% vs 6%
• PD-L1 CPS ≥5 biomarker selection
• Adjuvant immunotherapy without chemotherapy
Different strategies, same goal: improving cure rates in resectable gastric cancer.
#GastricCancer #GIOncology #CancerResearch #Oncology #medtwitter @OncoDailyGI
3
16
36
2,321
Ricardo Carvalho retweeted
Jun 10
Multidisciplinary Management of Esophageal Cancer | JCO Oncology Practice ascopubs.org/doi/abs/10.1200…
1
18
54
3,662
Ricardo Carvalho retweeted
📚 Esophageal cancer: where are we now?
🔹 Histology-driven treatment
🔹 Biomarker-guided therapy
• PD-L1
• HER2
• CLDN18.2
• MSI
🔹 Multidisciplinary management
🔹 Personalized care pathways
🎯 Better patient selection, better outcomes.
🔗 doi.org/10.1200/OP-26-00198
@OncoAlert
31
48
3,641
Ricardo Carvalho retweeted
Jun 11
🟦Nausea-Vomiting Prevention
ESMO-MASCC 2023 guideline summary
#cancer #oncology #MedX @OncoAlert @CancerCareMASCC
2
88
155
7,659
Ricardo Carvalho retweeted
Jun 10
2
63
153
5,755
Ricardo Carvalho retweeted
Jun 10
RTOG 0848: neg overall, but benefit in pN0 (adj chemoRT improved OS 5yr 48% v 29%).
Caveats: small N0 subgroup (N=91), gem chemo, pre neoadj era.
My main takeaway: RT has role in (select) resectable PDAC & future trials need to focus on biologically favorable subset. @OncoAlert
Jun 10
Adjuvant Chemotherapy /- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848 | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
3
25
68
13,302
Ricardo Carvalho retweeted
3
4
377
Ricardo Carvalho retweeted
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.
Read the full article. bit.ly/4dZ0AdP
#ColorectalCancer #crcsm
9
15
3,554
Ricardo Carvalho retweeted
Jun 8
What do you mean 92% ORR in pretreated pancreatic cancer?! 🤯
6
51
280
54,690
Ricardo Carvalho retweeted
Jun 9
What did ASCO 2026 change?
Some standards of care have now moved by years.
That almost never happens.
BRAF colorectal, pancreatic KRAS, and DDLPS sarcoma
are three of oncology's hardest diseases
SOC moved by > 1yr:
▫️BRAF mCRC: 15.1 → 30.3 months OS
▪️Pancreatic KRAS: 6.7 → 13.2 months OS 🏆
▪️DDLPS sarcoma: 1.5 → 9.7 months PFS ⭐️
(sarcoma went from "nothing" to a win).
Myeloma, GIST, HR /HER2- breast, uveal melanoma, bladder, prostate, and RET lung cancer moved too.
This is what decades of funded science look like when it compounds.
- - - - -
Source: Jori (@jori_health)
𝘗𝘭𝘰𝘵 𝘱𝘦𝘦𝘳-𝘳𝘦𝘷𝘪𝘦𝘸𝘦𝘥 𝘣𝘺 𝘦𝘪𝘨𝘩𝘵 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘦𝘹𝘱𝘦𝘳𝘵𝘴. 𝘛𝘩𝘢𝘯𝘬 𝘺𝘰𝘶 <3
- - - - -
5
71
208
18,756
Ricardo Carvalho retweeted
🧬 Staging laparoscopy post-CT (n=128)
📈 Peritoneal disease resolution: 37%
📈 mOS: 53.7 vs 21.5 mo
📉 New Peritoneal disease: 5.6%
⚠️ Persistent Peritoneal disease = adverse prog factor
⚠️ Lim: false-neg findings
🎯 Best tool for selecting pts w/ fav peritoneal response
🔗 link.springer.com/article/10…
@OncoAlert @GrupoTTD
6
11
890
Ricardo Carvalho retweeted
🧬 TRIPLETE OS debate
📩 Comment: OS advantage be driven by more frequent anti-EGFR reinduction after PD?
📩 Reply: Reinduction may play a role, but OS differences persisted even after excluding these pts.
🎯 The true reason for the late OS benefit remains unresolved.
🔗 doi.org/10.1200/JCO-26-00227
🔗 doi.org/10.1200/JCO-26-00870
@OncoAlert
8
14
1,059
Ricardo Carvalho retweeted
Our Ph3 ALTAIR trial for ctDNA-pos CRC is out now in Nature Medicine!
🔗doi.org/10.1038/s41591-026-0…
@NatureMedicine @OncoAlert
1
15
51
4,416
Ricardo Carvalho retweeted
Jun 8
Just insane… this is what we mean when we say that this is just the beginning. 💯 #RASRevolution
13
30
4,865
Ricardo Carvalho retweeted
GI Oncology Digest - June 9, 2026 🧬
2 Nat Med papers:
• ALTAIR (Nat Med Phase 3) — first MRD-guided post-adjuvant CRC trial reads NEGATIVE. ctDNA found the right patients; FTD/TPI was the wrong drug.
• SYNCHRONIZE-MASLD (Nat Med Phase 3) - survodutide drops 84% of obese MASLD patients to ≥30% less liver fat. The HCC-prevention curve bends.
A thread 🧵👇
#GIOnc #CRC #MASLD #ctDNA
1
1
4
268
Ricardo Carvalho retweeted
Jun 8
Data from Tango slide deck of PRMT5inh plus KRASinh (Daraxonrasib, left and Zoldonrasib, right) in 2nd/3rd line #PancreaticCancer
ir.tangotx.com/static-files/…
In this recent study (Boston Gene), ~20% of pancreatic cancers have KRAS mut plus MTAP co-deletion.
aacrjournals.org/clincancerr…
Jun 8
Top line data from Tango Therapeutics PRMT5 inh (Vopimetostat) plus @RevMedicines Daraxonrasib or Zoldonrasibin 2nd line #PancreaticCancer
ir.tangotx.com/news-releases…
Daraxonrasib (left) and Zoldonrasib (right) combination data. MultiRAS inhibition better than allele specific.
2
28
79
11,241